.After antibody-drug conjugate (ADC) expert Seagen was actually marketed to Pfizer last year for a m...
.On the heels of a stage 3 gain that neglected to thrill real estate investors, Ironwood Pharmaceuti...
.Don't cease Monte Rosa Therapeutics now. The Boston-based biotech is having a ball after signing a ...
.Welcome to this week's Chutes & Ladders, our roundup of significant management hirings, firings ...
.Celebrating his company's upsized initial public offering (IPO), Septerna CEO Jeffrey Finer called ...
.AbbVie has come back to the resource of its antipsychotic giant Vraylar looking for one more hit, p...
.GenSight Biologics is full weeks out of running out of money. Again. The biotech merely has suffici...
.Monopar Rehabs is actually recuperating a medicine from the scrap heap of AstraZeneca's uncommon ai...
.Along with brand-new data out on Arcus Biosciences' speculative HIF-2a inhibitor, one team of exper...
.After creating a genetics treatment collaboration with Dyno Rehabs in 2020, Roche is back for more....